Identification and management of poor response to growth‐promoting therapy in children with short stature
Open Access
- 27 April 2012
- journal article
- review article
- Published by Wiley in Clinical Endocrinology
- Vol. 77 (2) , 169-181
Abstract
Summary: Growth hormone (GH) is widely prescribed for children with short stature across a range of growth disorders. Recombinant human (rh) insulin‐like growth factor‐1 (rhIGF‐1) therapy is approved for severe primary IGF‐I deficiency – a state of severe GH resistance. Evidence is increasing for an unacceptably high rate of poor or unsatisfactory response to growth‐promoting therapy (i.e. not leading to significant catch up growth) in terms of change in height standard deviation score (SDS) and height velocity (HV) in many approved indications. Consequently, there is a need to define poor response and to prevent or correct it by optimizing treatment regimens within accepted guidelines. Recognition of a poor response is an indication for action by the treating physician, either to modify the therapy or to review the primary diagnosis leading either to discontinuation or change of therapy. This review discusses the optimal investigation of the child who is a candidate for GH or IGF‐1 therapy so that a diagnosis‐based choice of therapy and dosage can be made. The relevant parameters in the evaluation of growth response are described together with the definitions of poor response. Prevention of poor response is addressed by discussion of strategy for first‐year management with GH and IGF‐1. Adherence to therapy is reviewed as is the recommended action following the identification of the poorly responding patient. The awareness, recognition and management of poor response to growth‐promoting therapy will lead to better patient care, greater cost‐effectiveness and increased opportunities for clinical benefit.Keywords
This publication has 68 references indexed in Scilit:
- Non-Compliance with Growth Hormone Treatment in Children Is Common and Impairs Linear GrowthPLOS ONE, 2011
- ACMG practice guideline: Genetic evaluation of short statureGenetics in Medicine, 2009
- Observations of nonadherence to recombinant human growth hormone therapy in clinical practiceClinical Therapeutics, 2008
- A proteomic approach identified growth hormone-dependent nutrition markers in children with idiopathic short statureProteome Science, 2008
- Models predicting the growth response to growth hormone treatment in short children independent of GH status, birth size and gestational ageBMC Medical Informatics and Decision Making, 2007
- Final Height in Children with Idiopathic Growth Hormone Deficiency Treated with a Fixed Dose of Recombinant Growth HormoneHormone Research in Paediatrics, 2007
- Growth Hormone Treatment of Short Children Born Small for Gestational Age: Growth Responses with Continuous and Discontinuous Regimens Over 6 YearsThe Journal of Clinical Endocrinology & Metabolism, 2000
- Growth Response to Growth Hormone (GH) Treatment Relates to Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Short Children with Various GH Secretion CapacitiesThe Journal of Clinical Endocrinology & Metabolism, 1997
- Two-Year Treatment of Growth Hormone (GH) Receptor Deficiency with Recombinant Insulin-Like Growth Factor I in 22 Children: Comparison of Two Dosage Levels and to GH-Treated GH DeficiencyThe Journal of Clinical Endocrinology & Metabolism, 1997
- Prediction of the outcome of growth hormone therapy in children with idiopathic short stature: A multivariate discriminant analyisThe Journal of Pediatrics, 1995